Hostname: page-component-669899f699-b58lm Total loading time: 0 Render date: 2025-04-28T02:54:34.471Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotica van een nieuwe generatie Praktijkervaringen

Published online by Cambridge University Press:  16 January 2019

H.J. Kolthof  and
B.A. Blansjaar
H.J. Kolthof*
Affiliation:
P.C. Bloemendaal te Den Haag, voorheen assistent geneeskundige, S.P.K. , Het Kasperspad te Dordrecht en het St. Joris Gasthuis te Delft
B.A. Blansjaar
Affiliation:
St. Joris Gasthuis te Delft
*
P.C. Bloemendaal postbus 53002 2505 AA Den Haag
Get access Rights & Permissions [Opens in a new window]

Samenvatting

In de praktijk zijn de effecten van clozapine en risperidon vergeleken bij schizofrene patiënten die onvoldoende reageren op klassieke antipsychotica. Van de 25 op clozapine ingestelde patiënten gebruikte 63 procent na een half jaar nog medicatie. Bij driekwart van deze groep wend naast goede effecten op hallucinaties en wanen ook een gunstig effect op negatieve symptomen geconstateerd. Van de 25 op risperidon ingestelde patiënten gebruikte na een half jaar nog 54 procent medicatie. In tegenstelling tot tie clozapine-gebruikers werd er bij hen nauwelijks een duurzaam effect op negatieve symptomen gevonden. Wel werden relatief weinig bijwerkingen gemeld. Gezien de resultaten van dit onderzoek wordt een kritische houding ten aanzien van het gebruik van nieuwe antipsychotica aanbevolen.

Summary

Summary

In this study the treatment effects of either clozapine or risperidone in 50 neuroleptic-resistant schizophrenic patients were evaluated in an open clinical study. Out of all patients on clozapine 63% continued its use after half a year's treatment, attaining good antipsychotic effects. Beneficial effects on negative symptoms were perceived by 73% of this group. Much less effects on negative symptoms were found after 6 months’ treatment with risperidone. liven though 54% of the patients on risperidone continued their medication for at least half a year as well. Few side effects were noticed. In conclusion, a critical appraisal is recommended where the new generation of atypical antipsychotics is concerned.

Keywords

SchizofreniemedicatierisperidonclozapineSchizophreniamedicationrisperidoneclozapine
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 10 , Issue 1 , March 1998 , pp. 7 - 12
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Literatuur

1. Farmacotherapeutisch Kompas. Amstelveen: Ziekenfondsraad, 1995.Google Scholar
2. Louwerens, JW, Korf, J, Sloof, CJ. Geprotocolleerde farmacotherapie bij psychosen. Pharm Weekbl 1994; 129: 528–34.Google Scholar
3. Genecsmiddelenbulletin. Gebu Prikbord, 1994; 28: 11.Google Scholar
4. Lindenmayer, J-P, Grochowski, S, Mabugat, L. Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics. J clin Psychopharmacol 1994; 14: 201–4.Google Scholar
5. Meltzer, HY, Cola, PA. The pharmacoeconomics of clozapine: A review. J clin Psychial 1994; 55: suppl B, 161-5.Google Scholar
6. Meltzer, HY. Clozapine: is another view valid? Am J Psychiat 1995; 152: 821–5.Google Scholar
7. Carpenter, WT, Conley, RR, Buchanan, RW, et al. Patient response and Resource Management: Another View of Clozapine Treatment of Schizophrenia. Am J Psychiat 1995; 152: 827–32.Google Scholar
8. Schene, AH, Linszen, DH. Clozapine. een herontdekt antipsychoticum. MGV 1994; 11: 1223–32.Google Scholar
9. Naber, D, Hippius, H. The European experience with use of clozapine. Hosp Comm Psychiat 1990; 41: 886–90.Google Scholar
10. Meltzer, HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch gen Psychiat 1989; 46: 672.Google Scholar
11. Avnon, M, Rabinowitz, J. Effectiveness of clozapine in hospitalized people with chronic neuroleptic-resistant schizophrenia. Br J Psychiat 1995; 167: 760–4.Google Scholar
12. Heinrich, K, Klieser, E, Lehmann, E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: A double blind, randomized trial. Progr Neuro-Psychopharmacol Biol Psychiat 1994; 18: 129–37.Google Scholar
13. Peuskens, J. Risperidone in the Treatment of Patients with chronic schizophrenia: A multi-national, multi-centre, double-blind parallel-group study versus haloperidol. Br J Psychiat 1995; 166; 712-26.Google Scholar
14. Szymanski, S, Lieberman, J, Pollack, S, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiat 1996; 39: 249–54.Google Scholar